Woodline Partners LP Has $1.05 Million Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

Woodline Partners LP reduced its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 40.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 297,800 shares of the company's stock after selling 203,808 shares during the quarter. Woodline Partners LP owned about 0.60% of scPharmaceuticals worth $1,054,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SCPH. Legato Capital Management LLC bought a new position in scPharmaceuticals during the 4th quarter valued at $37,000. China Universal Asset Management Co. Ltd. bought a new position in scPharmaceuticals during the 4th quarter valued at $38,000. ProShare Advisors LLC bought a new stake in shares of scPharmaceuticals during the 4th quarter worth $48,000. Price T Rowe Associates Inc. MD bought a new stake in shares of scPharmaceuticals during the 4th quarter worth $54,000. Finally, Wells Fargo & Company MN boosted its stake in shares of scPharmaceuticals by 110.5% during the 4th quarter. Wells Fargo & Company MN now owns 18,407 shares of the company's stock worth $65,000 after acquiring an additional 9,663 shares in the last quarter. 89.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SCPH has been the subject of several research reports. Maxim Group reduced their price objective on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of scPharmaceuticals in a research note on Thursday, March 20th.

scPharmaceuticals Price Performance

Shares of SCPH traded down $0.01 during trading hours on Friday, hitting $3.54. 288,816 shares of the company were exchanged, compared to its average volume of 368,843. The company has a market capitalization of $186.88 million, a PE ratio of -1.86 and a beta of 0.17. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The firm has a fifty day simple moving average of $2.68 and a 200-day simple moving average of $3.12. scPharmaceuticals Inc. has a one year low of $1.94 and a one year high of $5.65.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The business had revenue of $11.75 million during the quarter, compared to analyst estimates of $11.63 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. As a group, sell-side analysts predict that scPharmaceuticals Inc. will post -1.53 earnings per share for the current year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.